APA (7th ed.) Citation

SY, R., E, C., S, G., H, S., J, L., I, M., . . . L, V. (2025). Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. Cancer, 131(16), e70015. https://doi.org/10.1002/cncr.70015

Chicago Style (17th ed.) Citation

SY, Rha, et al. "Lenvatinib Plus Pembrolizumab for Patients with Previously Treated Select Solid Tumors: Results from the Phase 2 LEAP-005 Study Recurrent Glioblastoma Cohort." Cancer 131, no. 16 (2025): e70015. https://doi.org/10.1002/cncr.70015.

MLA (9th ed.) Citation

SY, Rha, et al. "Lenvatinib Plus Pembrolizumab for Patients with Previously Treated Select Solid Tumors: Results from the Phase 2 LEAP-005 Study Recurrent Glioblastoma Cohort." Cancer, vol. 131, no. 16, 2025, p. e70015, https://doi.org/10.1002/cncr.70015.